One of the earliest venture capital funds active in Greater China is the proprietary venture capital and private equity arm of a world’s leading asset management organization with operations around the globe. Since inception, the firm has developed a broad footprint across Asia, with offices in Beijing, Shanghai, Hong Kong, Delhi, Mumbai and Tokyo. The firm specializes in green-field, early and growth stage investments.
Within life sciences, the firm works on a wide range of technology sectors including therapeutics, medical devices, diagnostics, biotech R&D services, healthcare IT, and healthcare services. The firm is very opportunistic in terms of subsectors and indications but historically has been active in biosimilars and biotech R&D. The firm evaluates technologies based on two main criteria: meaningful impact on human health; bold and innovative ideas. The firm has no specific preference in the investment stage. However, the firm generally invests in earlier stage for therapeutics and R&D and later stage for medical devices, but seeds have been done with exceptional founding teams.
The firm is seeking companies with a strong and experienced management team. The firm is flexible when it comes to post-investment board representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 